Sun Pharma gets US nod for leukaemia drugNovember 17th, 2009 MUMBAI - Indian drug major Sun Pharmaceuticals Tuesday said it has secured tentative approval from the United States Food and Drugs Administration for the generic version of Gleeven, used to treat chronic myeloid leukaemia. The drug will be available in two strengths of 100 mg and 400 mg and the market size for them is estimated at nearly $900 million, the pharmaceuticals company said in a filing with the stock exchanges.
Bristol-Myers splits off Mead Johnson, shareholders can swap Bristol shares for Mead stockNovember 15th, 2009 Bristol-Myers splits off Mead Johnson NutritionNEW YORK — Bristol-Myers Squibb Co. is splitting off its holdings in infant formula maker Mead Johnson Nutrition Co.
Covidien says it finished $210M acquisition of brain monitoring technology company AspectNovember 6th, 2009 Covidien closes $210M purchase of Aspect MedicalNEW YORK — Drug and medical device maker Covidien PLC said Friday it completed its $210 million purchase of Aspect Medical Systems, a company that makes brain monitoring technology. Covidien said its tender offer for Aspect stock, which was worth $12 per share, closed at midnight.
Medco Health Solutions' 3rd-quarter profit jumps 13.5 percent on new clients, pricingNovember 3rd, 2009 Medco Health 3Q profit jumps 13.5 percentNEW YORK — Medco Health Solutions Inc., the largest U.S. pharmacy benefits manager, said Tuesday its profit rose 13.5 percent as the company gained new clients and benefited from price inflation of brand-name drugs.
Wall Street expects Medco to benefit from demand for health care savings, generic drug salesNovember 2nd, 2009 Earnings Preview: Medco Health SolutionsNEW YORK — Medco Health Solutions Inc., the largest U.S. pharmacy benefits manager, is scheduled to report its third-quarter results Tuesday morning.
Novamed shares fall as 3rd-quarter profit dips, earnings-per-share misses forecastsOctober 29th, 2009 Novamed shares fall on 3Q profit dipNEW YORK — Shares of ambulatory surgery center operator Novamed Inc. fell Thursday after the company reported a slight dip in third-quarter profit and earnings per share missed Wall Street expectations.
Vitamin Shoppe raises better-than-expected $154.6M in IPO; shares soar in 1st day of tradingOctober 28th, 2009 Vitamin Shoppe IPO raises $154.6M, shares soarNEW YORK — Vitamin Shoppe Inc. raised $154.6 million in its initial public offering Wednesday, more than had been expected.
Inverness Medical turns profit in 3Q as flu revenue up almost sixfold, acquisitions lift salesOctober 27th, 2009 Surging flu revenue helps Inverness post 3Q profitWALTHAM, Mass. — Diagnostics company Inverness Medical Innovations Inc.
Illumina posts profit as merger charges come off its books but results, outlook miss viewOctober 27th, 2009 Illumina turns 3Q profit but outlook weakSAN DIEGO — Genetic analysis instrument maker Illumina Inc. reported a third-quarter profit on Tuesday, compared with a year-ago period which included hefty acquisition costs.
Celgene's 3rd-quarter profit jumps 58 percent on cancer drug sales, tops forecastsOctober 22nd, 2009 Celgene 3Q profit surges on cancer drug salesSUMMIT, N.J. — Biotech drugmaker Celgene Corp.
Omnicell says 3rd-qtr profit slides sharply as product sales tumbleOctober 22nd, 2009 Omnicell 3Q profit falls as sales slideMOUNTAIN VIEW, Calif. — Omnicell Inc., which makes pharmacy-management systems and other devices, said Thursday its third-quarter profit fell sharply as product sales declined as health care firms remained cautious on equipment spending.
Corcept Therapeutics will sell stock and warrants to fund study and submission for CorluxOctober 13th, 2009 Corcept to raise $18M in sale of stock and optionsMENLO PARK, Calif. — Corcept Therapeutics Inc.
How the Dow Jones industrials and other major stock indexes fared in Monday's tradingSeptember 21st, 2009 How the major stock indexes fared on MondayStocks mainly fell Monday but ended off their worst levels of the day thanks to gains in health care shares. A stronger dollar ignited a sell-off in commodities like oil and gold, which weighed on energy and material stocks.
Syneron Medical rises as analyst expects recovery for laser cosmetic market and raises ratingSeptember 18th, 2009 Syneron advances following upgrade to 'Outperform'NEW YORK — Shares of Syneron Medical Ltd. rose Friday after an Oppenheimer analyst upgraded the stock, saying he believes the market for laser cosmetic surgery procedures has hit a low point and will start to recover.
Analyst says MAP Pharma will rise when more details on migraine drug are reported next weekSeptember 2nd, 2009 Analyst says new Levadex data could lift MAP stockNEW YORK — MAP Pharmaceuticals Inc. plans to share additional data from testing of its migraine drug candidate Levadex next week, and a Wedbush Morgan analyst said the results could boost MAP's share price.
